… First, our study of dabrafenib was limited to BRAF V600E-mutant thyroid cancers, whereas
the selumetinib study was not limited to a specific genotype. Second, we used traditional …

… Background: The BRAF V600E mutation is the most frequent genetic alteration in papillary
thyroid carcinoma (PTC). The role of BRAF V600E mutation as a poor prognostic factor has …

… harbor mutations in the gene encoding the serine/threonine-kinase B-type Raf kinase (BRAF…
There is intriguing evidence that BRAF mutation testing of papillary thyroid carcinoma might …

… According to the correlation of the presence of BRAF V600E mutation and the disease …
value of BRAF V600E mutation (ie patients disease free and without BRAF V600E mutation) was …

… the BRAF V600E mutation in papillary thyroid carcinoma (PTC) and to determine the correlation
between this mutation and … The BRAF V600E mutation status was analyzed in 187 tumor …

… the association between BRAF mutation and more aggressive tumor behavior is … BRAF
mutation and more aggressive tumor behavior is limited to older patients, and therefore BRAF …

… Kaplan-Meier analysis of the impact of BRAF V600E mutation on disease recurrence–free
survival of patients with solitary intrathyroidal conventional papillary thyroid cancer. A) Tumors …

… thyroid tumors and benign nodules for BRAF mutation, report a novel method of screening
for the mutation, … Here, we demonstrate that progression from papillary thyroid carcinoma to …

… Schematic representation of thyroid tumor types and BRAF V600E frequency in benign and
malignant lesions. The thyroid gland is composed of two major cell types: the thyrocytes and …

… Our study offers further evidence that the BRAF V600E mutation is associated with an …
papillary thyroid carcinoma. Our study provides one of the largest unselected cohorts (ie BRAF …